drugset / Trial / NCT04446091
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous adenocarcinoma(MAC).
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |